Skip to main content

Table 1 Clinicopathological factors of 544 patients who underwent radical hepatectomy

From: A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy

Variables

Training cohort (n = 381)

Validation cohort (n = 163)

P

Age, years

51.3 ± 11.2

50.2 ± 11.5

0.301

Sex

  

0.410

 Male

324 (85.0%)

143 (87.7%)

 

 Female

57 (15.0%)

20 (12.3%)

 

BMI, Kg/m2

  

0.713

 < 18.5

27 (7.1%)

12 (7.4%)

 

 18.5–25

258 (67.7%)

116 (71.2%)

 

 ≥ 25

96 (25.2%)

35 (21.5%)

 

HBsAg

  

0.327

 Positive

328 (86.1%)

135 (82.8%)

 

 Negative

53 (13.9%)

28 (17.2%)

 

HBV-DNA (copies/ml)

   

 < 103

176 (46.2%)

79 (48.5%)

0.645

 ≥ 103

205 (53.8%)

84 (51.5%)

 

Liver cirrhosis

  

0.142

 Present

263 (69.0%)

102 (62.6%)

 

 Absent

118 (31.0%)

61 (37.4%)

 

Child-Pugh classification

  

0.204

 A

367 (96.3%)

161 (98.8%)

 

 B

14 (3.7%)

2 (1.2%)

 

Previous abdominal surgery

  

0.705

 Present

61 (16.0%)

24 (14.7%)

 

 Absent

320 (84.0%)

139 (85.3%)

 

Comorbidities

  

0.012

 Present

73 (19.2%)

17 (10.4%)

 

 Absent

308 (80.8%)

146 (89.6%)

 

AFP, ng/mL

  

0.091

 < 400

233 (61.2%)

87 (53.4%)

 

 ≥ 400

148 (38.8%)

76 (46.6%)

 

CEA, ng/mL

  

0.575

 Normal

297 (78.0%)

131 (80.4%)

 

 Abnormal

84 (22.0%)

32 (19.6%)

 

CA19–9, U/ml

  

0.588

 Normal

233 (61.2%)

104 (63.8%)

 

 Abnormal

148 (38.8%)

59 (36.2%)

 

TBIL, umol/L

14.0 (10.9–17.8)

13.7 (11.0–18.4)

0.794

DBIL, umol/L

5.4 (4.1–6.8)

5.3 (4.2–6.8)

0.853

ALT, IU/L

38.0 (27.0–56.8)

39.0 (25.0–62.0)

0.974

AST, IU/L

38.0 (30.0–58.0)

39.0 (30.0–59.0)

0.875

Albumin, g/L

  

0.909

 <35

27 (7.1%)

12 (7.4%)

 

 ≥ 35

354 (92.9%)

151 (92.6%)

 

NLR

2.2 (1.7–3.1)

2.3 (1.6–3.2)

0.776

PLR

92.9 (65.1–128.3)

84.7 (64.0–135.9)

0.

ASA grade

  

0.088

 II

316 (82.9%)

125 (76.7%)

 

 III

65 (17.1%)

38 (23.3%)

 

Largest tumor size, cm

5.0 (3.2–7.8)

5.6 (3.4–9.0)

0.106

Tumor number

  

0.965

 Solitary

358 (94.0%)

153 (93.9%)

 

 Multiple

23 (6.0%)

10 (6.1%)

 

Hepatectomy

  

0.297

 Anatomical

213 (55.9%)

99 (60.7%)

 

 Nonanatomical

168 (44.1%)

64 (39.3%)

 

Hemorrhage, ml

  

0.498

 <200

133 (34.9%)

52 (31.9%)

 

 ≥ 200

248 (65.1%)

111 (68.1%)

 

Intraoperative transfusion

  

0.606

 Yes

30 (7.9%)

15 (9.2%)

 

 No

351 (92.1%)

148 (90.8%)

 

Differentiation

  

0.927

 poor

169 (44.4%)

73 (44.8%)

 

 Well-moderate

212 (55.6%)

90 (55.2%)

 

MVI

  

0.477

 Present

124 (32.5%)

48 (29.4%)

 

 Absent

257 (67.5%)

115 (70.6%)

 

Capsule

  

0.789

 Incomplete

215 (56.4%)

94 (57.7%)

 

 Complete

166 (43.6%)

69 (42.3%)

 
  1. ASA American Society of Anesthesiologists, BMI Body mass index, AFP α-fetoprotein, ALT Alanine transaminase, AST Aspartate aminotransferase, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet lymphocyte ratio, MVI Microvascular invasion
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us